



Sequence ST25
SEQUENCE LISTING

<110> Doherty, Joni

Clinton, Gail M.

<120> HER-2 BINDING ANTAGONISTS

<130> 49321-16

<140> US 09/506,079

<141> 2000-02-16

<150> US 09/234,208

<151> 1999-01-20

<160> 10

<170> PatentIn version 3.1

<210> 1

<211> 79

<212> PRT

<213> Homo sapiens

<220>

<221> MISC_FEATURE

<222> (2)..(2)

<223> Applicants herein disclose Thr and Ser sequence variants at this position

Sequence.ST25

<220>

<221> MISC_FEATURE

<222> (5)..(5)

<223> Applicants herein disclose Leu and Pro sequence variants at this position

<220>

<221> MISC_FEATURE

<222> (6)..(6)

<223> Applicants herein disclose Pro and Leu sequence variants at this position

INS
P8

<220>

<221> MISC_FEATURE

<222> (16)..(16)

<223> Applicants herein disclose Leu and Gln sequence variants at this position

<220>

<221> MISC_FEATURE

<222> (18)..(18)

<223> Applicants herein disclose Met and Leu sequence variants at this position

<220>

<221> MISC_FEATURE

<222> (21)..(21)

<223> Applicants herein disclose Gly, Asp, Ala and Val sequence variants at this position

<220>

<221> MISC_FEATURE

Sequence.ST25

<222> (36)..(36)

<223> Applicants herein disclose Leu and Ile sequence variants at this position

<220>

<221> MISC_FEATURE

<222> (54)..(54)

<223> Applicants herein disclose Pro and Arg sequence variants at this position

<220>

<221> MISC_FEATURE

<222> (64)..(64)

<223> Applicants herein disclose Pro and Leu sequence variants at this position

<220>

<221> MISC_FEATURE

<222> (73)..(73)

<223> Applicants herein disclose Asp and Asn sequence variants at this position

<400> 1

Gly Xaa His Ser Xaa Xaa Pro Arg Pro Ala Ala Val Pro Val Pro Xaa
1 5 10 15

Arg Xaa Gln Pro Xaa Pro Ala His Pro Val Leu Ser Phe Leu Arg Pro
20 25 30

Ser Trp Asp Xaa Val Ser Ala Phe Tyr Ser Leu Pro Leu Ala Pro Leu
35 40 45

Ser Pro Thr Ser Val Xaa Ile Ser Pro Val Ser Val Gly Arg Gly Xaa
50 55 60

Asp Pro Asp Ala His Val Ala Val Xaa Leu Ser Arg Tyr Glu Gly

Sequence .ST25

65 70

75

<210> 2
<211> 419
<212> PRT
<213> Homo sapiens

<220>
<221> MISC_FEATURE
<222> (342)..(342)
<223> Applicants herein disclose Thr and Ser sequence variants at this position

Ins
P8

<220>
<221> MISC_FEATURE
<222> (345)..(345)
<223> Applicants herein disclose Leu and Pro sequence variants at this position

<220>
<221> MISC_FEATURE
<222> (346)..(346)
<223> Applicants herein disclose Pro and Leu sequence variants at this position

<220>
<221> MISC_FEATURE
<222> (356)..(356)
<223> Applicants herein disclose Leu and Gln sequence variants at this position

<220>

Sequence.ST25

<221> MISC_FEATURE

<222> (358)..(358)

<223> Applicants herein disclose Met and Leu sequence variants at this position

<220>

<221> MISC_FEATURE

<222> (361)..(361)

<223> Applicants herein disclose Gly, Asp, Ala and Val sequence variants at this position

<220>

<221> MISC_FEATURE

<222> (376)..(376)

<223> Applicants herein disclose Leu and Ile sequence variants at this position

*Ins
F8*

<220>

<221> MISC_FEATURE

<222> (404)..(404)

<223> Applicants herein disclose Pro and Leu sequence variants at this position

<220>

<221> MISC_FEATURE

<222> (413)..(413)

<223> Applicants herein disclose Asp and Asn sequence variants at this position

<220>

<221> MISC_FEATURE

<222> (394)..(394)

Sequence ST25
<223> Applicants herein disclose Pro and Arg sequence variants at this position

<400> 2

Met Glu Leu Ala Ala Leu Cys Arg Trp Gly Leu Leu Leu Ala Leu Leu
1 5 10 15

Pro Pro Gly Ala Ala Ser Thr Gln Val Cys Thr Gly Thr Asp Cys Lys
20 25 30

Leu Arg Leu Pro Ala Ser Pro Glu Thr His Leu Asp Met Leu Arg His
35 40 45

Leu Tyr Gln Gly Cys Gln Val Val Gln Gly Asn Leu Glu Leu Thr Tyr
50 55 60

Leu Pro Thr Asn Ala Ser Leu Ser Phe Leu Gln Asp Ile Gln Glu Val
65 70 75 80

Gln Gly Tyr Val Leu Cys Ala His Asn Gln Val Arg Gln Val Pro Leu
85 90 95

Gln Arg Leu Arg Ile Val Arg Gly Thr Gln Leu Phe Glu Asp Asn Tyr
100 105 110

Ala Leu Ala Val Leu Asp Asn Gly Asp Pro Leu Asn Asn Thr Thr Pro
115 120 125

Val Thr Gly Ala Ser Pro Gly Gly Leu Arg Glu Leu Gln Leu Arg Ser
130 135 140

Leu Thr Glu Cys Leu Lys Gly Gly Val Leu Ile Gln Arg Asn Pro Gln
145 150 155 160

Leu Cys Tyr Gln Asp Thr Ile Leu Trp Lys Asp Ile Phe His Lys Asn
165 170 175

Asn Gln Leu Ala Leu Thr Leu Ile Asp Thr Asn Arg Ser Arg Ala Cys
180 185 190

His Pro Cys Ser Pro Cys Cys Lys Gly Ser Arg Cys Trp Gly Glu Ser
195 200 205

Sequence ST25

Ser	Glu	Asp	Cys	Gln	Ser	Leu	Thr	Arg	Thr	Val	Cys	Ala	Gly	Gly	Cys
210					215						220				
Ala	Arg	Cys	Lys	Gly	Pro	Leu	Pro	Thr	Asp	Cys	Cys	His	Glu	Gln	Cys
225					230				235			240			
Ala	Ala	Gly	Cys	Thr	Gly	Pro	Lys	His	Ser	Asp	Cys	Leu	Ala	Cys	Leu
				245				250				255			
His	Phe	Asn	His	Ser	Gly	Ile	Cys	Glu	Leu	His	Cys	Pro	Ala	Leu	Val
						260		265			270				
Thr	Tyr	Asn	Thr	Asp	Thr	Phe	Glu	Ser	Cys	Pro	Asn	Pro	Glu	Gly	Arg
						275		280			285				
Tyr	Thr	Phe	Gly	Ala	Ser	Cys	Val	Thr	Ala	Cys	Pro	Tyr	Asn	Lys	Leu
					295				300						
Ser	Thr	Asp	Val	Gly	Ser	Cys	Thr	Leu	Val	Cys	Pro	Leu	His	Asn	Gln
					310				315			320			
Glu	Val	Thr	Ala	Glu	Asp	Gly	Thr	Gln	Arg	Cys	Glu	Lys	Cys	Ser	Lys
						325		330			335				
Pro	Cys	Ala	Arg	Gly	Xaa	His	Ser	Xaa	Xaa	Pro	Arg	Pro	Ala	Ala	Val
							340	345			350				
Pro	Val	Pro	Xaa	Arg	Xaa	Gln	Pro	Xaa	Pro	Ala	His	Pro	Val	Leu	Ser
							355	360			365				
Phe	Leu	Arg	Pro	Ser	Trp	Asp	Xaa	Val	Ser	Ala	Phe	Tyr	Ser	Leu	Pro
						370		375			380				
Leu	Ala	Pro	Leu	Asp	Pro	Thr	Ser	Val	Xaa	Ile	Ser	Pro	Val	Ser	Val
									395			400			
Gly	Arg	Gly	Xaa	Asp	Pro	Asp	Ala	His	Val	Ala	Val	Xaa	Leu	Ser	Arg
									405			410		415	
Tyr	Glu	Gly													

<210> 3

<211> 19

Sequence.ST25

<212> DNA

<213> Artificial Sequence

<220>

<223> HER-2-specific oligonucleotide primer

<400> 3

tgagcaccat ggagctggc

19

<210> 4

<211> 22

<212> DNA

<213> Artificial Sequence

*TWS
F8*

<220>

<223> HER-2-specific oligonucleotide primer

<400> 4

tccggcagaa atgccaggct cc

22

<210> 5

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> HER-2 cDNA-specific oligonucleotide primer

<400> 5

aacacagcgg tgtgagaagt gc

22

<210> 6

<211> 21

<212> DNA

<213> Artificial Sequence

Sequence.ST25

<220>
<223> HER-2 ECDIIIa-region-specific oligonucleotide primer

<400> 6
ataccgggac aggtcaacag c

21

<210> 7

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> HER-2 ECDIIIa-region-specific oligonucleotide primer

Ins
F8

<400> 7
tctgggtacc cactcactgc

20

<210> 8

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> HER-2 exon-specific oligonucleotide primer

<400> 8

ttcacactgg cacgtccaga cc

22

<210> 9

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> HER-2 cDNA-specific oligonucleotide primer

Sequence .ST25

<400> 9
gcacggatcc atagcagact gaggagg

27

<210> 10

<211> 240

<212> DNA

<213> Homo sapiens

<220>

<221> exon

<222> (1)..(240)

<223> ECDIIIa region coding sequence

Ins
F8

<220>

<221> misc_feature

<222> (62)..(62)

<223> Applicants disclose C, T, A and G variants at this position

<400> 10

ggt wcc cac tca cyg cyc ccc agg cca gct gca gtt cct gtc cct cwg
 Gly Xaa His Ser Xaa Xaa Pro Arg Pro Ala Ala Val Pro Val Pro Xaa
 1 5 10 15

48

cgc atr cag cct gnc cca gcc cac cct gtc cta tcc ttc ctc aga ccc
 Arg Xaa Gln Pro Xaa Pro Ala His Pro Val Leu Ser Phe Leu Arg Pro
 20 25 30

96

tct tgg gac mta gtc tct gcc ttc tac tct cta ccc ctg gcc ccc ctc
 Ser Trp Asp Xaa Val Ser Ala Phe Tyr Ser Leu Pro Leu Ala Pro Leu
 35 40 45

144

agc cct aca agt gtc cst ata tcc cct gtc agt gtg ggg agg ggc cyg
 Ser Pro Thr Ser Val Xaa Ile Ser Pro Val Ser Val Gly Arg Gly Xaa
 50 55 60

192

gac cct gat gct cat gtg gct gtt sac ctg tcc cgg tat gaa ggc tga
 Asp Pro Asp Ala His Val Ala Val Xaa Leu Ser Arg Tyr Glu Gly
 65 70 75

240